STAMPEDE2 Registration - FAQs for Patients

What is STAMPEDE2?

The STAMPEDE2 study aims to identify better ways of treating prostate cancer that has spread to other parts of the body (called metastatic) through testing new treatments. This study is being conducted in the UK and other countries. Participation in this research study is voluntary. If you decide not to take part, this will not affect the care you receive from your doctor and hospital. Your oncology doctor will discuss with you the best standard of care treatment options available.

How are the new treatments tested?

In STAMPEDE2 there are 2 new research treatments being tested. For each research treatment, we need to compare this with a control group (people receiving standard treatment alone). The control group acts as the comparison for the research groups and is the way the study can assess the research treatment. This is a very important part of a randomised controlled trial and ensures the results are reliable.

If you take part in the study, a computer will randomly allocate you to a treatment group. You will have a 50% chance of being allocated to the treatment group (i.e. to receive additional treatment).  This allows a fair comparison between new treatments and the existing treatment to see which one works best.

What will I need to do if I take part?

If you decide that you would like to register for STAMPEDE2, you will be asked to read and sign a consent form. The consent form will ask you to confirm that you understand the information in this leaflet and agree to take part in the trial. You will get a copy of this signed consent form to keep. We want to keep the information about you confidential, so that only those people who really need to know can identify you. So, to keep your personal details confidential, an ID is created which does not directly identify you.

Depending on the treatment group you are eligible for, you will need to attend clinic regularly so that your research team can assess how you are responding to treatment and update the Medical Research Council Clinical Trials Unit (MRC CTU) at University College London (UCL) STAMPEDE2 researchers about your progress. 

Further information

For more FAQs and answers related to registering into the STAMPEDE2 study, please find the Registration Patient Information Sheet (PIS) here:

STAMPEDE2 Registration PIS V6.0 

The Registration PIS contains further material on the trial treatments, the possible advantages of participating, and more information on taking part in STAMPEDE2.